Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Montalban-Bravo Guillermo; Bose Prithviraj; Alvarado Yesid; Daver Naval; Ravandi Farhad; Borthakur Gautam; Takahashi Koichi; Andreeff Michael; Cortes Jorge E.; DiNardo Courtney D.; Jabbour Elias; Kadia Tapan M.; Kornblau Steven M.; Ohanian Maro; Pierola Ana Alfonso; Huang Xuelin; Nogueras-Gonzalez Graciela M.; Bodden Kristy; Littles Kristina; Pierce Sherry; Bueso-Ramos Carlos E.; Kantarjian Hagop M.; Garcia-Manero Guillermo

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

【24h】

Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

机译：瓜地西他滨（SGI-110）（一种新型皮下（sc）次甲基化剂）用于先前未治疗的中度2或高危骨髓增生异常综合征（MDS）或慢性粒细胞性白血病（CMML）的患者的2期研究的初步结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共6页
作者
Montalban-Bravo Guillermo; Bose Prithviraj; Alvarado Yesid; Daver Naval; Ravandi Farhad; Borthakur Gautam; Takahashi Koichi; Andreeff Michael; Cortes Jorge E.; DiNardo Courtney D.; Jabbour Elias; Kadia Tapan M.; Kornblau Steven M.; Ohanian Maro; Pierola Ana Alfonso; Huang Xuelin; Nogueras-Gonzalez Graciela M.; Bodden Kristy; Littles Kristina; Pierce Sherry; Bueso-Ramos Carlos E.; Kantarjian Hagop M.; Garcia-Manero Guillermo;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) [J] . Montalban-Bravo Guillermo, Bose Prithviraj, Alvarado Yesid, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：瓜地西他滨（SGI-110）（一种新型皮下（sc）次甲基化剂）用于先前未治疗的中度2或高危骨髓增生异常综合征（MDS）或慢性粒细胞性白血病（CMML）的患者的2期研究的初步结果
2. Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) [J] . Montalban-Bravo Guillermo, Bose Prithviraj, Alvarado Yesid, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：瓜地西他滨（SGI-110）（一种新型皮下（sc）次甲基化剂）用于先前未治疗的中度2或高危骨髓增生异常综合征（MDS）或慢性粒细胞性白血病（CMML）的患者的2期研究的初步结果
3. Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) [J] . Garcia-Manero Guillermo, Ritchie Ellen K., Walsh Katherine J., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：随机阶段2剂量 - 瓜鹃花，一种新型皮下（SC）低甲基化剂（HMA），在102例中间或高风险脓毒症综合征（MDS）或慢性骨髓细胞白血病（CMML）中的102例患者中的长期结果
4. Characteristics and outcomes of patients with multiple myeloma (MM) who develop therapy (t)-related myelodysplastic syndrome (MDS) t-chronic myelomonocytic leukemia (CMML) or t-acute myeloid leukemia (AML) [O] . Naveen Pemmaraju, Dhaval Shah, Hagop Kantarjian, -1

机译：患有治疗性（t）相关性骨髓增生异常综合症（MDS）t型慢性粒细胞性白血病（CMML）或t型急性髓性白血病（AML）的多发性骨髓瘤（MM）患者的特征和结局
5. Pre-Transplant Azacitidine and Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes of One Hundred Fifty-Nine Patients up to Age Seventy-Five with Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) [O] . Field Teresa, Perkins Janelle, Hillgruber Ryan, 2014

机译：一百五十九名直至75岁的骨髓增生异常综合症（MDS）或慢性粒细胞性白血病（CMML）患者的移植前阿扎胞苷和同种异体造血细胞移植（HCT）结果

Initial Results of a Phase 2 Study of Guadecitabine (SGI-110), a Novel Subcutaneous (sc) Hypomethylating Agent, for Patients with Previously Untreated Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

著录项

相似文献

相关主题

期刊订阅